Aerobic Exercises for Multiple Sclerosis

Multiple Sclerosis, Primary Progressive Clinical Trial

Official title:

Effect of Aerobic Exercises on Immune System in Patients With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04545372
• Other study ID #: P.T.REC/012/001072
• Status: Completed
• Phase: N/A
• Start date: February 2, 2015
• Est. completion date: August 6, 2020

Study information

• Verified date: September 2020
• Source: South Valley University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that results in progressive neural degeneration. Cytokines play an important role in the pathogenesis and treatment of MS.

Description:

This research aims to evaluate the effect of aerobic exercises on the immune system anti-inflammatory (IL-10) and pro inflammatory (IL-17) cytokines and its consequences on the functional status in the Multiple Sclerosis patients.

Aerobic exercises are a term to describe planned, structured and repetitive physical activity undertaken over a prolonged period to maintain or improve physical fitness and functional capacity .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 6, 2020
• Est. primary completion date: August 4, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 45 Years

Eligibility

Inclusion Criteria:

age ranged from 25 to 45 years. All the patients were remitting relapsing MS according to (revised McDonald criteria.

Duration of MS disease was one to two years before starting of the study. Last attack occurred three months ago. All patients were able to ambulate

Exclusion Criteria:

Patients with other neurological deficits , patient with significant orthopedic abnormalities for both lower limbs, patient with contracture , patient with deformities, pregnant females

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Primary Progressive
• Sclerosis

Intervention

Other:
• aerobic exercise

Locations

Country	Name	City	State
Egypt	South Valley University, Faculty of Physical Therapy	Qina,

Sponsors (1)

Lead Sponsor	Collaborator
South Valley University

Country where clinical trial is conducted

Egypt, 

References & Publications (5)

Barry A, Cronin O, Ryan AM, Sweeney B, Yap SM, O'Toole O, Allen AP, Clarke G, O'Halloran KD, Downer EJ. Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology. Front Physiol. 2016 Jun 2;7:194. doi: 10.3389/fphys.2016.00194. eCollection 2016. Review. — View Citation

Broughton SE, Hercus TR, Lopez AF, Parker MW. Cytokine receptor activation at the cell surface. Curr Opin Struct Biol. 2012 Jun;22(3):350-9. doi: 10.1016/j.sbi.2012.03.015. Epub 2012 Apr 20. Review. — View Citation

Haegert DG. Multiple sclerosis: a disorder of altered T-cell homeostasis. Mult Scler Int. 2011;2011:461304. doi: 10.1155/2011/461304. Epub 2011 Sep 15. — View Citation

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. — View Citation

Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E433-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood analysis	serum anti inflammatory cytokine IL-10,	serum anti inflammatory cytokine IL-10, will be assessed at 0 day
Primary	blood analysis	serum anti inflammatory cytokine IL-10,	serum anti inflammatory cytokine IL-10, wil lbe assessed at 90 day
Primary	blood analysis	pro inflammatory cytokine IL-17	pro inflammatory cytokine IL-17 will be assessed at 0 day
Primary	blood analysis	pro inflammatory cytokine IL-17	pro inflammatory cytokine IL-17 will be assessed at 90 day